World Cancer Report Webinar Series - HPV vaccination

"Learnings from Australia’s HPV vaccination experience" and "Trends in HPV vaccination from a global perspective"

On our HPV resources page we have published several articles by our speaker Dr Julia Brotherton. 



Thirteen sexually transmitted human papillomavirus (HPV) subtypes are responsible for all cases of cervical cancer globally (570 000 cases) and a proportion of cases of other anogenital and oropharyngeal cancers (totalling 120 000 cases). 

The safety and high efficacy of HPV vaccines have been established in clinical trials. Data are accruing on the effectiveness of HPV vaccination programmes, including strong herd immunity effects, and reduction in cervical cancer rates. HPV vaccination programmes are the cornerstone of the World Health Organization (WHO) Global Strategy on Cervical Cancer Elimination. 

This webinar will describe the impact of HPV vaccination in Australia, which implemented one of the earliest and most successful vaccination programmes. This will be followed by an up-to-date overview of global progress in the implementation of HPV vaccination, with a focus on challenges in low- and middle-income countries


Dr Gary Clifford. Head of the Infections and Cancer Epidemiology Group

International Agency for Research on Cancer (IARC), World Health Organization
Lyon, France


Dr Julia Brotherton, public health physician and epidemiologist

Medical Director, Population Health, VCS Foundation, Melbourne, Australia

“Key learnings from Australia’s HPV vaccination experience”

Australia is in its 14th year of HPV vaccination, which started with a catch-up programme. Before 2018, the programme used three-dose quadrivalent HPV vaccine, with male vaccination commencing in 2013. Since 2018, the routine school-based programme has used two-dose nonavalent vaccine. This presentation will assess whether Australia’s coverage, and programme impacts so far, are consistent with achieving elimination of cervical cancer in Australia.

Areas of expertise: 

  • Delivery and evaluation of population-based cancer screening and immunization programmes
  • Impact of human papillomavirus (HPV) vaccination programme

Professional posts:

  • Lead investigator in Australian research that demonstrated evidence of significant declines in HPV infections and pre-cancerous cervical lesions in young women after vaccination
  • Honorary Principal Fellow at the School of Population and Global Health, University of Melbourne
  • Member of the WHO Director-General’s Expert Advisory Group on Cervical Cancer Elimination

Mr Paul Bloem, public health practitioner

HPV Vaccine Strategy Lead, World Health Organization, Geneva, Switzerland

Key trends in HPV vaccination from a global perspective”

How have other countries followed Australia’s example, and what has been learned about HPV vaccination in lower-resource settings? An overview of introduction status by region and income levels will point to both challenges and successes, followed by an assessment of the key drivers affecting introductions in the coming years. Against the goal of eliminating cervical cancer, Paul will assess the feasibility of reaching global cervical cancer elimination targets, and discuss possible future innovations in HPV vaccination programmes.

Areas of expertise: 

  • Health Systems Management, including setting norms and standards for HPV vaccination programmes
  • Technical support for vaccine introduction in low- and middle-income countries
  • Adolescent health, including control and integration of HPV vaccination with other health interventions

Professional posts:

  • WHO Strategy Lead for HPV Vaccines in the Department of Immunization, Vaccines and Biologicals 
  • Chair of the GAVI HPV subteam advising on the implementation of GAVI’s HPV programme
  • Chair of the Vaccines Working Group of the Secretariat for the Global Strategy on Cervical Cancer Elimination
Scroll to Top